WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004002528) COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/002528    International Application No.:    PCT/US2003/020604
Publication Date: 08.01.2004 International Filing Date: 30.06.2003
Chapter 2 Demand Filed:    28.01.2004    
IPC:
A61K 31/704 (2006.01), A61K 39/395 (2006.01), A61K 47/48 (2006.01), C07K 16/30 (2006.01)
Applicants: SAVIENT PHARMACEUTICALS, INC. [US/US]; One Tower Center Blvd., East Brunswick, NJ 08816 (US)
Inventors: LAZAROVITS, Janette; (IL).
NIMROD, Abraham; (IL).
HOCH-MAR-CHAIM, Hagit; (IL).
LEVANON, Avigdor; (IL)
Agent: SOMERVILLE, Deborah, A.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US)
Priority Data:
10/189,025 01.07.2002 US
Title (EN) COMPOSITIONS AND METHODS FOR THERAPEUTIC TREATMENT
(FR) COMPOSITIONS ET PROCEDES POUR TRAITEMENT THERAPEUTIQUE
Abstract: front page image
(EN)The present invention relates to compositions utilizing an agent and an antibody, or fragment thereof. In these compositions, the agents, including agents such as anti-cancer, anti-metastasis, anti-leukemia, anti-disease, anti-adhesion, anti-thrombosis, anti -restenosis, anti-autoimmune, anti-aggregation, anti-bacterial, anti-viral, and anti-inflammatory agents, can be complexed or combined with or conjugated to the antibodies, or fragments thereof. In addition, the agent and/or the antibody, or fragment thereof, can be present in the composition in a sub-clinical amount, which is an amount that is less than the amount of the agent generally found to be clinically effective when the agent is administered alone. Preferably, in these compositions of the present invention, the agent is an anthracycline or a derivative thereof, e.g., doxorubicin (adriamycin) or a derivative thereof.
(FR)L'invention concerne des compositions faisant intervenir un agent et un anticorps, ou un fragment dudit anticorps. Dans ces compositions, les agents, notamment des agents anti-cancéreux, anti-métastases, anti-leucémiques, anti-maladies, anti-adhérents, anti-thromboses, anti-resténoses, anti-maladies auto-immunes, anti-aggrégants, anti-bactériens, anti-viraux et anti-inflammatoires, peuvent être complexés ou combinés aux anticorps ou conjugués à ceux-ci, ou à des fragments de ceux-ci. En outre, l'agent et/ou l'anticorps, ou le fragment de celui-ci, peut être présent dans la composition à une quantité sous-clinique, qui est une quantité inférieure à la quantité de l'agent généralement efficace sur le plan clinique lorsque cet agent est administré seul. De préférence, dans ces compositions, l'agent est un agent anthracycline ou un dérivé de celui-ci, par exemple de la doxorubicine (adriamycin) ou un dérivé de celle-ci.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)